Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

NEW YORK — Novacyt said on Friday that it has been unable to secure an extension for its SARS-CoV-2 test supply contract with the UK Department of Health and Social Care (DHSC), threatening one of the French diagnostic firm's key revenue drivers.

About a year ago, Novacyt struck a deal to supply SARS-CoV-2 assays to the DHSC for an initial term of six months. According to Novacyt, active discussions to extend that contract have failed, although it did supply its Promate SARS-CoV-2 detection workflow in the first quarter of this year at DHSC's request.

Novacyt noted that it generated €83.0 million ($98.5 million) in the first quarter of 2021, about half of which came from sales of Promate and other products to the DHSC. The remaining revenues were from international sales and private sector testing operations. 

Novacyt said it is disputing the contract with DHSC, which may negatively impact its fourth quarter 2020 revenues. The firm added that it has "strong grounds to assert its contractual rights."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.